Product Information
IBUPROFEN 800 MG TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.0573 per EA under NDC 76282071450. Its NADAC has been published 217 times since Aug 10, 2022.
FDA first approved this application on Sep 15, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
800 mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282071450
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA091625FDA Approved
9/15/2015
TE Code
AB
On Market Since
3/10/2022
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN 800 MG TABLET has been published 217 times since Aug 10, 2022, and over the history we have for it it has declined 21.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0573 per EA |
|---|---|
| All-time high | $0.0747 (Mar 15, 2023) |
| All-time low | $0.0511 (Nov 20, 2024) |
| 52-week high | $0.0587 |
| 52-week low | $0.0549 |
| Median price | $0.0632 |
| Average price | $0.0630 |
| Largest weekly change | -20.3% (Apr 17, 2024) |
| Weeks tracked | 217 |
| Tracking since | Aug 10, 2022 |
Generic Alternatives
The matcher finds 15 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN 800 MG TABLET, manufactured by Exelan Pharmaceuticals Inc., is $0.0573 per EA (NDC 76282071450), effective Sep 30, 2026.
How has the price of IBUPROFEN 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for IBUPROFEN 800 MG TABLET has declined 21.8%. It has been tracked across 217 weekly CMS publications since Aug 10, 2022.
What are the highest and lowest recorded NADAC prices for IBUPROFEN 800 MG TABLET?
Since Aug 10, 2022, the NADAC for IBUPROFEN 800 MG TABLET has ranged from a low of $0.0511 (Nov 20, 2024) to a high of $0.0747 (Mar 15, 2023), with a median of $0.0632 per EA.
Are there cheaper alternatives to IBUPROFEN 800 MG TABLET?
Yes. 15 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN 800 MG TABLET, is $0.0567 per EA — about 1% below IBUPROFEN 800 MG TABLET.
Who manufactures IBUPROFEN 800 MG TABLET?
IBUPROFEN 800 MG TABLET (NDC 76282071450) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.